A couple of months after Thousand Oaks-based Atara Biotherapeutics announced it would be laying off roughly 80 employees, the company confirmed nearly half of those jobs are coming from its Ventura ...

The revision follows concerns related to the delayed approval of Atara's Ebvallo and the possibility that the company may discontinue its CAR-T development in the first quarter of 2025.

“We will further narrow our focus on the future financial value of EBVALLO for the benefit of all stakeholders. Atara continues to productively engage with our partner Pierre Fabre Laboratories ...

Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt trials of the allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate. Atara ...

U.S. FDA issues clinical hold on EBVALLO™ (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell ...

The approval of Ebvallo reflects the tremendous growth and momentum we see across the CGT industry, as developers continue to usher in new therapies that offer life-extending and potentially ...

According to the Company, "The CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO." The FDA took the additional ...

The company's off-the-shelf or 'allogeneic' therapy tabelecleucel – now given the Ebvallo trade name – has been approved by the European Commission as a second-line treatment for a rare and ...

Stay updated on market trends for ATRA. FDA halts Atara's EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre upon EBVALLO approval.

Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO ™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value ...